Clinical trial

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2017-12-18

PhasePHASE3

Study timeline

Study start (actual)2017-12-18Date precision: day

Registry last updated2026-09-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

mCRPCunresolved

Interventions

Talazoparib with enzalutamideDRUG

Placebo with enzalutamideDRUG

Sponsors & collaborators

Pfizerlead sponsor

Astellas Pharma Inccollaborator

Mapped research locations

SeoulSouth Korea9 PortlandOregon, United States6 AuroraColorado, United States5 MadridSpain4 BudapestHungary4 ShanghaiChina4 Porto AlegreRio Grande do Sul, Brazil4 NashvilleTennessee, United States3 LondonUnited Kingdom3 PittsburghPennsylvania, United States3 San DiegoCalifornia, United States3 MontrealQuebec, Canada3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03395197 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.